Literature DB >> 17670934

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.

Przemyslaw Juszczynski1, Jing Ouyang, Stefano Monti, Scott J Rodig, Kunihiko Takeyama, Jeremy Abramson, Wen Chen, Jeffery L Kutok, Gabriel A Rabinovich, Margaret A Shipp.   

Abstract

Classical Hodgkin lymphomas (cHLs) contain small numbers of neoplastic Reed-Sternberg (RS) cells within an extensive inflammatory infiltrate that includes abundant T helper (Th)-2 and T regulatory (Treg) cells. The skewed nature of the T cell infiltrate and the lack of an effective host antitumor immune response suggest that RS cells use potent mechanisms to evade immune attack. In a screen for T cell-inhibitory molecules in cHL, we found that RS cells selectively overexpressed the immunoregulatory glycan-binding protein, galectin-1 (Gal1), through an AP1-dependent enhancer. In cocultures of activated T cells and Hodgkin cell lines, RNAi-mediated blockade of RS cell Gal1 increased T cell viability and restored the Th1/Th2 balance. In contrast, Gal1 treatment of activated T cells favored the secretion of Th2 cytokines and the expansion of CD4+CD25high FOXP3+ Treg cells. These data directly implicate RS cell Gal1 in the development and maintenance of an immunosuppressive Th2/Treg-skewed microenvironment in cHL and provide the molecular basis for selective Gal1 expression in RS cells. Thus, Gal1 represents a potential therapeutic target for restoring immune surveillance in cHL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670934      PMCID: PMC1936978          DOI: 10.1073/pnas.0706017104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?

Authors:  Gabriel A Rabinovich; Linda G Baum; Nicola Tinari; Roberto Paganelli; Clara Natoli; Fu Tong Liu; Stefano Iacobelli
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

2.  Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

Authors:  Maher K Gandhi; Eleanore Lambley; Jaikumar Duraiswamy; Ujjwal Dua; Corey Smith; Suzanne Elliott; Devinder Gill; Paula Marlton; John Seymour; Rajiv Khanna
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

Review 3.  Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.

Authors:  Jeremy S Abramson; Margaret A Shipp
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

4.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Authors:  Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

5.  Galectin-1: a link between tumor hypoxia and tumor immune privilege.

Authors:  Quynh-Thu Le; Gongyi Shi; Hongbin Cao; Daniel W Nelson; Yingyun Wang; Eunice Y Chen; Shuchun Zhao; Christina Kong; Donna Richardson; Ken J O'Byrne; Amato J Giaccia; Albert C Koong
Journal:  J Clin Oncol       Date:  2005-10-11       Impact factor: 44.544

6.  AP-1 blockade inhibits the growth of normal and malignant breast cells.

Authors:  J H Ludes-Meyers; Y Liu; D Muñoz-Medellin; S G Hilsenbeck; P H Brown
Journal:  Oncogene       Date:  2001-05-17       Impact factor: 9.867

7.  Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.

Authors:  Takashi Ishida; Toshihiko Ishii; Atsushi Inagaki; Hiroki Yano; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Authors:  Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

9.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

Authors:  Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

10.  The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death.

Authors:  Maho Amano; Marisa Galvan; Jiale He; Linda G Baum
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

View more
  111 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Debora Martorelli; Elena Muraro; Patrizia Comoli; Antonio Rosato
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 3.  Systems biology in immunology: a computational modeling perspective.

Authors:  Ronald N Germain; Martin Meier-Schellersheim; Aleksandra Nita-Lazar; Iain D C Fraser
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 4.  Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions.

Authors:  Alexander V Timoshenko
Journal:  Cell Mol Life Sci       Date:  2015-08-06       Impact factor: 9.261

5.  Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer.

Authors:  Dong Tang; Jun Gao; Sen Wang; Zhongxu Yuan; Nianyuan Ye; Yang Chong; Chuanqi Xu; Xuetong Jiang; Bin Li; Wei Yin; Yi Miao; Daorong Wang; Kuirong Jiang
Journal:  Tumour Biol       Date:  2015-03-01

Review 6.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 7.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

8.  Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Authors:  Margaretha G M Roemer; Robert A Redd; Fathima Zumla Cader; Christine J Pak; Sara Abdelrahman; Jing Ouyang; Stephanie Sasse; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Stephen Ansell; Kazunobu Kato; Benedetto Farsaci; Anne Sumbul; Philippe Armand; Donna S Neuberg; Geraldine S Pinkus; Azra H Ligon; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2018-02-02       Impact factor: 44.544

Review 9.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

10.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.